Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 9 » default
Pharmacogenomics and Personalized Medicine
ISSN: 1178-7066
- View all (640)
- Volume 17, 2024 (19)
- Volume 16, 2023 (97)
- Volume 15, 2022 (82)
- Volume 14, 2021 (155)
- Volume 13, 2020 (72)
- Volume 12, 2019 (34)
- Volume 11, 2018 (24)
- Volume 10, 2017 (31)
- Volume 9, 2016 (14)
- Volume 8, 2015 (16)
- Volume 7, 2014 (37)
- Volume 6, 2013 (15)
- Volume 5, 2012 (12)
- Volume 4, 2011 (10)
- Volume 3, 2010 (11)
- Volume 2, 2009 (9)
- Volume 1, 2008 (2)
Archive: Volume 9, 2016
CYP2D6 polymorphisms and their influence on risperidone treatment
Puangpetch A, Vanwong N, Nuntamool N, Hongkaew Y, Chamnanphon M, Sukasem C
Pharmacogenomics and Personalized Medicine 2016, 9:131-147
Published Date: 1 December 2016
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
Lally J, Gaughran F, Timms P, Curran SR
Pharmacogenomics and Personalized Medicine 2016, 9:117-129
Published Date: 7 November 2016
Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study
Finkelstein J, Friedman C, Hripcsak G, Cabrera M
Pharmacogenomics and Personalized Medicine 2016, 9:107-116
Published Date: 14 October 2016
Pharmacogenomics of statins: understanding susceptibility to adverse effects
Kitzmiller JP, Mikulik EB, Dauki AM, Mukherjee C, Luzum JA
Pharmacogenomics and Personalized Medicine 2016, 9:97-106
Published Date: 3 October 2016
The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction
Sychev DA, Zastrozhin MS, Smirnov VV, Grishina EA, Savchenko LM, Bryun EA
Pharmacogenomics and Personalized Medicine 2016, 9:89-95
Published Date: 14 September 2016
Comments on Lucire and Crotty, 2011
Loonen AJM, Verkes RJ
Pharmacogenomics and Personalized Medicine 2016, 9:85-87
Published Date: 18 August 2016
Use of combinatorial pharmacogenomic testing in two cases from community psychiatry
Fields ES, Lorenz RA, Winner JG
Pharmacogenomics and Personalized Medicine 2016, 9:79-84
Published Date: 16 August 2016
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
Patel JN
Pharmacogenomics and Personalized Medicine 2016, 9:65-77
Published Date: 12 July 2016
The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia
Sychev DA, Shuev GN, Chertovskih JV, Maksimova NR, Grachev AV, Syrkova OA
Pharmacogenomics and Personalized Medicine 2016, 9:59-63
Published Date: 25 May 2016
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment
Tulsyan S, Mittal RD, Mittal B
Pharmacogenomics and Personalized Medicine 2016, 9:47-58
Published Date: 27 April 2016
Potential utility of precision medicine for older adults with polypharmacy: a case series study
Finkelstein J, Friedman C, Hripcsak G, Cabrera M
Pharmacogenomics and Personalized Medicine 2016, 9:31-45
Published Date: 15 April 2016
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Dawed AY, Zhou K, Pearson ER
Pharmacogenomics and Personalized Medicine 2016, 9:17-29
Published Date: 6 April 2016
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
Myers MB
Pharmacogenomics and Personalized Medicine 2016, 9:7-16
Published Date: 22 January 2016
Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility
Saldivar JS, Taylor D, Sugarman EA, Cullors A, Garces JA, Oades K, Centeno J
Pharmacogenomics and Personalized Medicine 2016, 9:1-6
Published Date: 19 January 2016